2-oxabicyclo[2.2.2]oct-5-en-3-one | 63838-51-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃
• 英文名称: 2-oxabicyclo[2.2.2]oct-5-en-3-one
• 英文别名: 2-oxabicyclo<2.2.2>oct-5-en-3-one；2-Oxabicyclo<2.2.2>oct-5-en-3-on
• CAS: 63838-51-7
• 化学式: C₇H₈O₂
• 分子量: 124.139
• InChiKey: OBNPFXSOHOEJOI-UHFFFAOYSA-N

物化性质

• 沸点：
  100-110 °C(Press: 16 Torr)
• 密度：
  1.196±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-oxabicyclo[2.2.2]oct-5-en-3-one 在 4-二甲氨基吡啶 、 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 132.0h， 生成 cis-<4-hydroxy-2-cyclohexen-1-yl>methylcarbonic acid methyl ester
  参考文献：
  名称：

  环己烯基核苷：顺式-4-（9 H-嘌呤-9-基）-2-环己烯基甲醇的合成

  摘要：

  从环己二烯和氯磺酰基异氰酸酯开始，标题化合物的合成以6-7个步骤完成。该策略的关键步骤涉及将环己烯基碳酸氢盐8与6-氯嘌呤或2-氨基-6-氯嘌呤进行钯偶联。

  DOI：

  10.1016/0040-4020(95)00926-4
• 作为产物：
  描述：

  2-Oxabicyclo[2.2.2]oct-5-en-3-ylidenesulfamyl chloride 在 盐酸 作用下， 以 丙酮 为溶剂， 反应 2.0h， 生成 2-oxabicyclo[2.2.2]oct-5-en-3-one
  参考文献：
  名称：

  环己烯基核苷：顺式-4-（9 H-嘌呤-9-基）-2-环己烯基甲醇的合成

  摘要：

  从环己二烯和氯磺酰基异氰酸酯开始，标题化合物的合成以6-7个步骤完成。该策略的关键步骤涉及将环己烯基碳酸氢盐8与6-氯嘌呤或2-氨基-6-氯嘌呤进行钯偶联。

  DOI：

  10.1016/0040-4020(95)00926-4

文献信息

• Chiral CO₂-Synthons via Catalytic Asymmetric Hetero-Diels−Alder Reactions of Ketomalonate and Dienes
  作者：Sulan Yao、Mark Roberson、Frank Reichel、Rita G. Hazell、Karl Anker Jørgensen

  DOI：10.1021/jo990696i

  日期：1999.9.1

  A catalytic enantioselective approach for the formation of chiral CO(2)-synthons is presented. The described methodology is based on the reaction of dienes with diethyl ketomalonate using C(2)-symmetric bisoxazolines as the chiral ligands and copper(II) and zinc(II) as the Lewis acids. For cyclic dienes the reaction proceeds in good yield and with up to 93% ee for 1,3-cyclohexadiene, while for cyclopentadiene

  提出了一种手性CO（2）合成子形成催化对映选择性方法。所描述的方法是基于二烯与酮丁二酸二乙酯的反应，使用C（2）对称的双恶唑啉作为手性配体，铜（II）和锌（II）作为路易斯酸。对于环状二烯，反应以良好的收率进行，并且对于1，3-环己二烯，ee高达93％，而对于环戊二烯，该反应在低温下也进行得很好，但是升高温度会导致逆Diels-Alder反应。已经在不同条件下和针对各种二烯对反应进行了研究，并且发现对于活化的二烯，杂-Diels-Alder和Mukaiyama Aldol产物均被分离。由1的对映选择性杂Diels-Alder反应形成的化合物 3-ketolononate的3-环己二烯已转化为原理上从CO（2）和1,3-环己二烯的[2 + 4]环加成反应形成的CO（2）-合成子，以及有吸引力的光学活性1,4-二取代环己二醇。杂-Diels-Alder加合物的绝对构型是基于1,4-二取代的环己
• Adenine derivatives as protein kinase inhibitors
  申请人：B.C.I. PHARMA

  公开号：US11236093B2

  公开（公告）日：2022-02-01

  The present invention relates to a compound suitable for use as a kinase inhibitor according to general formula (I) [compound (C), herein after], or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof, formula (I) wherein A, R1, R2, R3, R3′, R4, R4′, X, Y, Z, T are as defined in the claims. The invention further relates to an in vitro method of inhibiting protein kinase activity which comprises contacting a protein kinase with a compound of formula (I), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof. The invention further relates to the compounds of formula (I) per se, as well as to their use as a medicament, and for use or in a method of treatment of a disease mediated by a protein kinase selected from cancer, inflammatory disorders, cardiovascular diseases, viral induced diseases, circulatory diseases, fibro-proliferative diseases and pain sensitization disorders.

  本发明涉及根据通式(Ⅰ)[化合物(C)，以下同]的适于用作激酶抑制剂的化合物，或其N-氧化物、药学上可接受的盐、药学上可接受的溶液或立体异构体，式(Ⅰ)其中A、R1、R2、R3、R3′、R4、R4′、X、Y、Z、T如权利要求书中所定义。本发明进一步涉及一种抑制蛋白激酶活性的体外方法，该方法包括使蛋白激酶与式(I)化合物或其N-氧化物、药学上可接受的盐、药学上可接受的溶液或立体异构体接触。本发明进一步涉及式（I）化合物本身及其作为药物的用途，以及用于治疗由蛋白激酶介导的选自癌症、炎症性疾病、心血管疾病、病毒引起的疾病、循环系统疾病、纤维增生性疾病和痛觉过敏性疾病的方法。
• Synthesis of unsaturated lactones via palladium-catalyzed cyclization of alkenoic acids
  作者：Richard C. Larock、Timothy R. Hightower

  DOI：10.1021/jo00072a004

  日期：1993.9

  Acyclic and cyclic, aliphatic or aromatic, 4- or 5-alkenoic acids cyclize in high yield to 5- or 6-membered unsaturated lactones using 5 mol % Pd (OAc) 2, 2 equiv of NaOAc, and 1 atm Of O2.
• ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
  申请人：B.C.I. PHARMA

  公开号：US20190127379A1

  公开（公告）日：2019-05-02

  The present invention relates to a compound suitable for use as a kinase inhibitor according to general formula (I) [compound (C), herein after], or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof, formula (I) wherein A, R 1 , R 2 , R 3 , R 3′ , R 4 , R 4′ , X, Y, Z, T are as defined in the claims. The invention further relates to an in vitro method of inhibiting protein kinase activity which comprises contacting a protein kinase with a compound of formula (I), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof. The invention further relates to the compounds of formula (I) per se, as well as to their use as a medicament, and for use or in a method of treatment of a disease mediated by a protein kinase selected from cancer, inflammatory disorders, cardiovascular diseases, viral induced diseases, circulatory diseases, fibro-proliferative diseases and pain sensitization disorders.